Tempus Acquired Ambry Genetics, Revolutionizing the Field of Precision Medicine
February 03, 2025, CHICAGO, Tempus AI has officially acquired a well-known international genetics testing company. Tempus acquired Ambry Genetics, marking a pivotal step in advancing precision medicine, combining cutting-edge technology with genetic expertise. Tempus a company advancing precision medicine through the collection and analysis of molecular and clinical data, has completed its acquisition of Ambry Genetics, a renowned clinical genetics testing company.
How Tempus Acquired Ambry Genetics to Transform Precision Medicine?
After several discussions, Tempus acquired Ambry Genetics, uniting two leaders in advanced medical technology and genetics,
Buying the medication will create a powerhouse of scientific knowledge and medical expertise, facilitating the creation of more personalized and successful treatment plans.
The company paid $375 million in cash and $225 million in shares at closing of which $100 million is subject to a lock-up agreement until one year post-transaction close. Ares Management Credit Funds granted funding for the transaction.
Eric Lefkofsky, CEO of Tempus, highlighted that we will accelerate the development of precision medicine and improve patient outcomes together.
It is reasonable to assume that the acquisition of more genetic testing and explore new health issues such as immunology, pediatrics, cardiac problems, and concerns related to women’s reproductive system.
Meta Claims that Open-source AI is changing the results of healthcare. Tempus is a technology that is transforming medical treatment. The company has one of the largest libraries of multimodal data with the help of an operating system to make that data accessible and useful.
The acquisition will increase the capacity to screen for inherited cancer risk. Tempus said on Monday that Ambry, an established reference lab in the field of hereditary cancer screening with its headquarters in Aliso Viejo, California, is being acquired in this way.
Source: TelecomTalk
